MX362920B - Derivado de tetrahidroimidazo[1,5-d] [1,4]oxazepina. - Google Patents

Derivado de tetrahidroimidazo[1,5-d] [1,4]oxazepina.

Info

Publication number
MX362920B
MX362920B MX2015010741A MX2015010741A MX362920B MX 362920 B MX362920 B MX 362920B MX 2015010741 A MX2015010741 A MX 2015010741A MX 2015010741 A MX2015010741 A MX 2015010741A MX 362920 B MX362920 B MX 362920B
Authority
MX
Mexico
Prior art keywords
alkyl group
tetrahydroimidazo
mglur2
hydrogen atom
oxazepine derivative
Prior art date
Application number
MX2015010741A
Other languages
English (en)
Other versions
MX2015010741A (es
Inventor
Takaishi Mamoru
Sato Nobuhiro
Shibuguchi Tomoyuki
Motoki Takafumi
Takahashi Yoshinori
Sasaki Takeo
Braunton Alan
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2015010741A publication Critical patent/MX2015010741A/es
Publication of MX362920B publication Critical patent/MX362920B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Un compuesto representado por la siguiente formula (I) o una sal farmacéuticamente aceptable de este funciona como un antagonista de mGluR2, y es aplicable como agente terapéutico para trastornos neurológicos relacionados con la disfunción de glutamato y enfermedades que involucran mGluR2, como enfermedad de Alzheimer: (ver Fórmula) donde R es un átomo de hidrógeno, un grupo alquilo C1-6 o similar, R1 es un grupo alquilo C1-6, un grupo alcoxi C1-6 o similar, R2 es un átomo de halógeno, un grupo alquilo C1-6, un grupo alcoxi C1-6 o similar, R3 es un átomo de hidrógeno, un grupo alquilo C1-6 o similar, y R4 es un grupo alquilo a C1-6 o similar.
MX2015010741A 2013-02-28 2014-02-26 Derivado de tetrahidroimidazo[1,5-d] [1,4]oxazepina. MX362920B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361770469P 2013-02-28 2013-02-28
PCT/JP2014/054724 WO2014133022A1 (ja) 2013-02-28 2014-02-26 テトラヒドロイミダゾ［１，５－ｄ］［１，４］オキサゼピン誘導体

Publications (2)

Publication Number Publication Date
MX2015010741A MX2015010741A (es) 2016-01-08
MX362920B true MX362920B (es) 2019-02-26

Family

ID=51388759

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010741A MX362920B (es) 2013-02-28 2014-02-26 Derivado de tetrahidroimidazo[1,5-d] [1,4]oxazepina.

Country Status (30)

Country Link
US (1) US9458176B2 (es)
EP (1) EP2963043B1 (es)
JP (1) JP5654715B1 (es)
KR (1) KR102190597B1 (es)
CN (1) CN105008375B (es)
AR (1) AR094887A1 (es)
AU (1) AU2014221775B2 (es)
BR (1) BR112015020545A2 (es)
CA (1) CA2901168C (es)
CL (1) CL2015002391A1 (es)
CY (1) CY1121231T1 (es)
DK (1) DK2963043T3 (es)
ES (1) ES2685025T3 (es)
HK (1) HK1217697A1 (es)
HR (1) HRP20181349T1 (es)
HU (1) HUE040219T2 (es)
IL (1) IL240402A (es)
LT (1) LT2963043T (es)
MX (1) MX362920B (es)
PE (1) PE20151651A1 (es)
PH (1) PH12015501878A1 (es)
PL (1) PL2963043T3 (es)
PT (1) PT2963043T (es)
RS (1) RS57602B1 (es)
RU (1) RU2659219C2 (es)
SG (1) SG11201505252VA (es)
SI (1) SI2963043T1 (es)
TW (1) TWI622592B (es)
UA (1) UA114950C2 (es)
WO (1) WO2014133022A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
TWI622578B (zh) 2011-12-21 2018-05-01 諾維拉治療公司 Ｂ型肝炎抗病毒劑
BR112015004192B1 (pt) 2012-08-28 2021-02-09 Janssen Sciences Ireland Uc sulfamoíl-arilamidas, composição farmacêutica que os compreende e uso das mesmas no tratamento da hepatite b
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
BR112015025052A2 (pt) 2013-04-03 2021-07-06 Janssen Sciences Ireland Uc derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EA035500B1 (ru) 2013-05-17 2020-06-25 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
EP3357906B1 (en) 2013-07-25 2019-12-04 Janssen Sciences Ireland Unlimited Company Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015120178A1 (en) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Combination therapy for treatment of hbv infections
CN105980378B (zh) 2014-02-06 2019-09-27 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
JP2017206438A (ja) * 2014-08-22 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ［１，５−ｄ］［１，４］オキサゼピン化合物（ＴＥＴＲＡＨＹＤＲＯＩＭＩＤＡＺＯ［１，５−ｄ］［１，４］ＯＸＡＺＥＰＩＮＥＣＯＭＰＯＵＮＤ）
WO2016033190A1 (en) * 2014-08-27 2016-03-03 Eisai, Inc. Radiotracer compounds
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
CN107427505A (zh) 2015-02-25 2017-12-01 卫材R&D管理有限公司 用于抑制喹啉衍生物的苦味的方法
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN107847762A (zh) 2015-03-19 2018-03-27 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
SG11201808949SA (en) 2016-04-15 2018-11-29 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
TW201837036A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物（一）
EP3568395A1 (de) 2017-01-10 2019-11-20 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
JP2021035911A (ja) * 2017-11-15 2021-03-04 大日本住友製薬株式会社 縮環ピラゾール誘導体及びその医薬用途
JP7242548B2 (ja) 2017-11-24 2023-03-20 住友ファーマ株式会社 ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体及びその医薬用途
AU2019235522A1 (en) 2018-03-14 2020-09-03 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
TWI820231B (zh) 2018-10-11 2023-11-01 德商拜耳廠股份有限公司 用於製備經取代咪唑衍生物之方法
MA55020A (fr) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
AR119732A1 (es) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
US11155547B1 (en) * 2020-06-18 2021-10-26 Alterity Therapeutics Limited Compounds for and methods of treating diseases
CN116033828A (zh) 2020-07-02 2023-04-28 拜耳公司 作为害虫防治剂的杂环衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268626C (zh) * 2001-04-12 2006-08-09 弗·哈夫曼-拉罗切有限公司 用作mGluR2拮抗剂I的二氢－苯并[b][1,4]二氮杂䓬－2－酮衍生物
RU2412943C2 (ru) 2005-03-23 2011-02-27 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ АЦЕТИЛЕНИЛ-ПИРАЗОЛО-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2
ATE463495T1 (de) * 2005-09-27 2010-04-15 Hoffmann La Roche Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
CA2657835C (en) 2008-03-07 2017-09-19 Mathieu Audet Documents discrimination system and method thereof
AU2009319387B2 (en) * 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
WO2010068520A2 (en) * 2008-12-11 2010-06-17 Cara Therapeutics, Inc. Substituted imidazoheterocycle derivatives
JP2012513399A (ja) * 2008-12-22 2012-06-14 シェーリング コーポレイション γ−セクレターゼ調節剤

Also Published As

Publication number Publication date
CA2901168A1 (en) 2014-09-04
TW201443062A (zh) 2014-11-16
PL2963043T3 (pl) 2018-10-31
HUE040219T2 (hu) 2019-02-28
EP2963043B1 (en) 2018-05-30
US9458176B2 (en) 2016-10-04
RS57602B1 (sr) 2018-11-30
HK1217697A1 (zh) 2017-01-20
CA2901168C (en) 2020-09-22
SI2963043T1 (sl) 2018-09-28
IL240402A0 (en) 2015-09-24
LT2963043T (lt) 2018-10-10
CY1121231T1 (el) 2020-05-29
UA114950C2 (uk) 2017-08-28
SG11201505252VA (en) 2015-08-28
PT2963043T (pt) 2018-10-09
CN105008375B (zh) 2016-12-28
CL2015002391A1 (es) 2016-02-05
KR102190597B1 (ko) 2020-12-15
HRP20181349T1 (hr) 2018-10-19
EP2963043A1 (en) 2016-01-06
DK2963043T3 (en) 2018-09-03
JP5654715B1 (ja) 2015-01-14
US20140243316A1 (en) 2014-08-28
CN105008375A (zh) 2015-10-28
MX2015010741A (es) 2016-01-08
AR094887A1 (es) 2015-09-02
AU2014221775A1 (en) 2015-07-23
PE20151651A1 (es) 2015-11-07
AU2014221775B2 (en) 2017-08-24
TWI622592B (zh) 2018-05-01
WO2014133022A1 (ja) 2014-09-04
EP2963043A4 (en) 2016-07-20
BR112015020545A2 (pt) 2017-07-18
IL240402A (en) 2017-09-28
JPWO2014133022A1 (ja) 2017-02-02
KR20150120381A (ko) 2015-10-27
RU2015135967A (ru) 2017-04-03
RU2659219C2 (ru) 2018-06-29
PH12015501878A1 (en) 2015-12-07
ES2685025T3 (es) 2018-10-05

Similar Documents

Publication Publication Date Title
PH12015501878A1 (en) Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
JO3116B1 (ar) مشتق بيرازولوكينولين كمثبطات ل pde9
MY166866A (en) Heterocyclic derivative and pharmaceutical drug
MX2018003215A (es) Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
PH12014501719A1 (en) Pyridone derivatives
ECSP13013038A (es) Inhibidores sustituidos de acetil-coa carboxilasa
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
PH12015501836A1 (en) 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
MX2016007861A (es) Compuestos de ácido dimetilbenzoico.
MX2016003422A (es) Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen.
MY170822A (en) Ethynyl derivatives as mglur5 allosteric modulators
MX2016008536A (es) Derivados de fluoro-naftilo.
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
IN2014DN05972A (es)
PH12016501481B1 (en) Ethynyl derivatives
PH12020550761A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF
MX2015015485A (es) Derivado de glicinamida alfa-sustituida.
MX2014014808A (es) Compuestos triciclicos como inhibidores de kat ii.

Legal Events

Date Code Title Description
FG Grant or registration